Trial Profile
A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 22 May 2023 Status changed from recruiting to active, no longer recruiting.
- 10 Dec 2021 Trial design presented at the 44th Annual San Antonio Breast Cancer Symposium
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology